Significantly greater tolerance to inhibitors found in whole blood and anticoagulants (K2-EDTA, sodium heparin, and sodium citrate)
A) Lyo-Ready™ Direct DNA qPCR Blood (MDX122)
B) Lyo-Ready™ Direct RNA/DNA qPCR Blood (MDX123)
45
45
40
40
35
35
30
30
25
25
10%
2%
5%
10
2%
5%
2%
5%
10%
0%
2%
5%
0%
2%
5%
0%
2%
5%10%
%
10%
10%
®
TaqPath™
TaqPath™
MDX122
KAPA Probe Force (Roche)
MDX123
UltraPlex (Quantabio)
(ThermoFisher)
(ThermoFisher)
EDTA | Heparin | Citrate
Anticoagulants and high concentrations of whole blood are known to inhibit qPCR efficiencies. In this experiment, 0%, 2%, 5% and 10% whole human blood in the presence of K2-EDTA ( orange ), sodium heparin ( green ) or sodium citrate ( grey ) was tested with (A) Lyo-Ready TM Direct DNA qPCR Blood (MDX122) against KAPA Probe Force (Roche) and TaqPath™ (Thermo) and (B) Lyo-Ready™ Direct RNA/DNA qPCR Blood (MDX123) against UltraPlex™ 1-Step ToughMix® (QuantaBio) and TaqPath™ 1-Step Multiplex Master Mix (Thermo). The results demonstrate that the reaction efficiencies of the Lyo-Ready TM Direct Blood mixes are higher in the presence of inhibitors found in anticoagulants and high concentrations of blood.
High multiplexing capacity enables the detection of multiple analytes from crude, inhibitor- rich plasma, serum and whole blood samples
Lyo-Ready™ Direct DNA qPCR Blood (MDX122) S. aureus
P. falciparum
Epstein-Bar virus
Lyo-Ready TM Direct DNA qPCR Blood | KAPA Probe Force | TaqPath TM ProAMP TM Mix
Three diagnostic DNA targets ( Staphylococcus aureus , Plasmodium falciparum and Epstein-Bar virus) were amplified in a triplex reaction using lyophilized Lyo-Ready™ Direct DNA qPCR Blood (MDX122, red ), KAPA Probe Force ( green ) or TaqPath™ ProAmp TM Mix ( black ) in the presence of 10% EDTA plasma or 10% serum. The results illustrate that Lyo-Ready™ Direct DNA qPCR Blood has higher multiplexing capacity and performance than KAPA Probe Force and TaqPath™ ProAmp™ Mix.
www.meridianbioscience.com/lifescience 3
Powered by FlippingBook